The Brain Study

Stroke is the second leading cause of death globally, with nearly 5.5 million deaths every year. Current treatments have their limitations, mainly because they should be administered within a short time after the occurrence of the stroke.

The study drug is a potential new treatment for acute ischemic stroke (AIS). At the onset of AIS, the blood supply in the local brain tissue is obstructed. This leads to reduced oxygen and blood flow in the brain tissue, which can result in a series of complex and serious reactions.

Because ethnicity can have an impact on how medication is processed, this study requires participants who are of Caucasian or of European, Middle Eastern, or North African descent. This data will be compared with participants with Chinese ethnicity. Other studies do not have these ethnicity requirements.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!